The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 2018

Filed:

Jun. 17, 2014
Applicants:

Andrew Bett, Lansdale, PA (US);

Beth-ann Griswold Coller, Kaneohe, HI (US);

Govindarajan Dhanasekaran, Harleysville, PA (US);

Ramesh V. Chintala, Chalfont, PA (US);

Inventors:

Andrew Bett, Lansdale, PA (US);

Beth-Ann Griswold Coller, Kaneohe, HI (US);

Govindarajan Dhanasekaran, Harleysville, PA (US);

Ramesh V. Chintala, Chalfont, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/00 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/70 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01);
Abstract

The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine is a live, attenuated dengue vaccine and the second dengue vaccine is a recombinant dengue subunit vaccine or an inactivated dengue vaccine; wherein the live attenuated dengue vaccine comprises at least one live, attenuated dengue virus or at least one live attenuated chimeric flavivirus. The dengue virus vaccine compositions of the invention may further comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.


Find Patent Forward Citations

Loading…